Physician profile
Lisa A Gombita
NPI 1437367109
$2,173.80
in general payments reported to CMS, 2019-2025
14 companies · $734 in 2025
The $734 reported for 2025 was more than what 80% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $373 · 2022: $225 · 2023: $394 · 2024: $448 · 2025: $734.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,387 · Education: $133 · Consulting Fee: $55.41.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,387.23 |
| Education | $133.48 |
| Consulting Fee | $55.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $481.70 | 2021-2024 | Jakafi |
| Astrazeneca Pharmaceuticals Lp | $319.27 | 2021-2025 | Imfinzi, Calquence |
| Merck Sharp & Dohme LLC | $230.07 | 2023-2024 | Lynparza |
| Exelixis INC. | $169.51 | 2025 | Cabometyx |
| Adma Biomanufacturing LLC | $163.83 | 2022-2023 | |
| Celgene Corporation | $160.42 | 2021-2025 | Breyanzi, Reblozyl |
| Ipsen Biopharmaceuticals, INC | $145.42 | 2025 | Onivyde |
| Adc Therapeutics America, INC. | $116.48 | 2022 | |
| Stemline Therapeutics INC. | $114.55 | 2024 | Orserdu |
| Eisai INC. | $95.25 | 2025 | |
| Abbvie INC. | $89.72 | 2024 | |
| Novartis Pharmaceuticals Corporation | $64.62 | 2025 | |
| Gilead Sciences, INC. | $11.92 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $11.04 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lisa Gombita listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.